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Abstract
Microtubule-associated protein tau (MAPT) mutations have been shown to underlie frontotemporal dementia and a variety of additional sporadic
auopathies. We identified a rare p.A152T variant in MAPT exon 7 in two (of eight) patients with clinical presentation of parkinsonism and
postmortem finding of neurofibrillary tangle pathology. Two siblings of one patient also carried the p.A152T variant, and both have progressive
cognitive impairment. Further screening identified the variant in two other cases: one with pathologically confirmed corticobasal degeneration and
another with the diagnosis of Parkinson’s disease with dementia. The balance of evidence suggests this variant is associated with disease, but the
very varied phenotype of the cases with the mutation is not consistent with it being a fully penetrant pathogenic mutation. Interestingly, this
variation results in the creation of a new phosphorylation site that could cause reduced microtubule binding. We suggest that the A152T variant
is a risk factor associated with the development of atypical neurodegenerative conditions with abnormal tau accumulation.
© 2012 Published by Elsevier Inc.
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d1. Introduction
Tau belongs to the family of the microtubule-binding
proteins (MT) (Witman et al., 1976) and is encoded by the
T-associated protein tau (MAPT) gene located on chro-
osome 17 (17q21) (Andreadis et al., 1992). MAPT muta-
tions have been linked to a variety of neurodegenerative
diseases with abnormal tau accumulation, and mainly to
frontotemporal dementia (FTD) (Hutton et al., 1998) but
also to other sporadic tauopathies, including progressive
supranuclear palsy (PSP), corticobasal degeneration (CBD),
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http://dx.doi.org/10.1016/j.neurobiolaging.2012.04.006and various disorders with more unusual tau pathology
(Conrad et al., 1997; Höglinger et al., 2011; Momeni et al.,
2009). Recently, an A152T variation in MAPT exon 7 was
dentified in a patient who had dementia and unclassifiable
auopathy (Kovacs et al., 2011). With this background, we
etermined to sequence the MAPT gene in our small
series of cases with indeterminate tauopathies (eight
cases). Here, we report two patients with atypical par-
kinsonian disorder and abnormal tau accumulation at
postmortem, both of whom were identified to carry the
A152T variation. We then screened a larger series of
tauopathy cases for this mutation (PSP and CBD) and
some cases with idiopathic Parkinson’s disease to deter-
mine the nature of the phenotype that seemed to be
associated with this variant and found an additional case
with CBD as well as a case of Parkinson’s disease in
which there was prominent tangle pathology.
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All subjects in this report had provided written consent to
perform neuropathological and genetic studies. The access
to clinical records and pathological material at the Queen
Square Brain Bank (QSBB) has generic ethical approval
from a London Multi-Centre Research Ethics Committee
under a license from the Human Tissue Authority.
2.1. Neuropathology
After postmortem the brains were divided midsagittally.
One half brain was immediately frozen and stored at
80 °C, whereas the other half was immersed and fixed in
10% neutral formalin for 3 weeks. Tissue blocks were
processed using standard protocols. We performed hema-
toxylin and eosin, Luxol fast blue/cresyl violet, Congo red
staining on 7-m-thick sections and also used the modified
Bielschowsky and Gallyas silver impregnation methods.
Immunohistochemistry with antibodies to phospho-tau
(AT8 clone recognizing Ser202/Thr205), 3-repeat (3R) and
4-repeat (4R) tau isoforms (de Silva et al., 2003), ubiquitin,
p62, TAR DNA-binding protein-43 (TDP-43), and -sy-
nuclein was also carried out using a standard avidin-biotin
method.
2.2. Patients from unclassified tauopathy series
In our initial DNA-sequencing study, we sequenced the
entire MAPT gene open reading frame in eight cases that
had received a clinical diagnosis of postencephalitic parkin-
sonism (PEP) or clinical parkinsonism with unclassifiable
tauopathy at postmortem. PEP is a rare clinical entity char-
acterized by the development of parkinsonism after the
development of encephalitis (Geddes et al., 1993). Initial
postmortem studies indicated PEP in case 1, described later
in the article, and was previously reported as such (Geddes
et al., 1993). The original neuropathological investigation
did not reach a conclusive diagnosis in case 2, which had
been categorized as “parkinsonism associated with unclas-
sifiable neurofibrillary tangle pathology”.
2.3. Genetic analysis
Genomic DNA was extracted from brain tissue of the
eight archival cases. In these cases, the PARK2 and LRRK2
genes had also been previously fully sequenced without
finding any changes. Three of these eight cases have been
previously reported (case 5, 7, and 8) (Geddes et al., 1993).
After the p.A152T mutation was found in exon 7 in two of
these cases, additional screening of this exon was carried
out in blood-derived DNA of the three siblings of case 1
(two suffering from dementing illnesses and one unaf-
fected), and in 150 neuropathologically defined control sub-
jects and 133 1958 Wellcome Trust blood donor control
subjects. At this stage, the occurrence and frequency of this
variant in public databases were also assessed.2.4. Statistical analysis
Fisher exact tests were conducted using an online tool
research.microsoft.com/enus/um/redmond/projects/mscompbio/
FisherExactTest/. A p-value less than 0.01 was considered
statistically significant.
2.5. Secondary screening
After we had identified the variant in the unclassified
tauopathy cases described earlier and failed to find the
variant in control subjects, we screened for the mutation by
sequencing MAPT exon 7 in DNA derived from the brains
of the QSBB archival collection, including 114 cases with
PSP (Pittman et al., 2004), 8 cases with CBD (Houlden et
al., 2001), and 48 cases with idiopathic Parkinson’s disease,
all of which had received pathological confirmation of their
diagnoses.
3. Results
3.1. Primary sequencing
3.1.1. Genetics
Among the eight cases subjected to primary genetic
analysis, two cases (25%) reported earlier were identified to
carry a heterozygote nonsynonymous variant in exon 7
(rs143624519, c.454GA, p.A152T) (accession numbers
NM_005910.5 and NP_005901.2, respectively) (Fig. 1A
and 1B). This variant was also found in the two sisters of
case 1, who are both developing progressive cognitive im-
pairment, but this variant was absent in the third unaffected
sister. All patients are Caucasian and of Northern European
descent. This variant is present with a frequency of 19 in
3510 (0.54%) individuals of European American origin (19
in 7020 alleles) in the publically available database from the
National Heart, Lung, and Blood Institute (NHLBI) “Grand
Opportunity” Exome Sequencing Project (GO-ESP) (Ex-
ome Variant Server, NHLBI ESP, Seattle, WA [URL:
evs.gs.washington.edu/EVS/] [accessed on 01/2012]). We
additionally screened 150 neuropathologically confirmed
control subjects from the UK and 133 belonging to the 1958
Wellcome cohort and did not find this variant. The Fisher
exact test used to compare both allele and genotype fre-
quencies between the clinically diagnosed PEP and the ESP
cohort gave a two-tailed p-value of  0.01 for allele and
genotype frequencies. A search through two publically
available databases (1000 genomes and National Institute of
Environmental Health Sciences (NIEHS) Environmental
Genome Project, Seattle, WA [URL: evs.gs.washing-
ton.edu/niehsExome/] [accessed on 03/2012]) revealed sim-
ilarly low frequencies of the A152T variant (Supplementary
Table 1) (1000 Genomes Project Consortium, 2010). This
variant has been reported more frequently in Alzheimer’s
disease (AD) patients than in control subjects (Cruchaga et
al., 2012).
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3.1.2.1. Clinical summary and neuropathology. The clini-
cal and neuropathological features of this case were reported in
a series of PEP (case 8) (Geddes et al., 1993). At age 26 years,
this patient developed progressive levodopa-responsive parkin-
sonism with intact cognition. She had a long history of
levodopa-induced orofacial dystonia. The disease duration was
54 years, and she died at age 80. A family history of dementia
was noted but not elaborated in her medical records. In hind-
sight, the absence of encephalitis history would make the
clinical diagnosis of PEP unlikely.
Neuropathological review of this case has confirmed
significant degree of neuronal loss in the substantia nigra,
which was most severe in the ventrolateral tier. The tau
pathology in the substantia nigra included neurofibrillary
tangles (NFTs) and numerous, either fine or coarse, neuropil
threads (NTs). Sparse NFTs and NTs were also seen in the
midbrain tegmentum and, in addition, amyloid plaque-as-
sociated abnormal neurites were observed in the midbrain
tectum. There were scattered NFTs and tau-positive threads
in the striatum; occasional NFTs and threads were also seen
in the globus pallidus and subthalamic nucleus. There was a
single NFT with sparse NTs in the cerebellar dentate nu-
cleus. There were amyloid- (A)-positive diffuse and ma-
ture plaques in the frontal, parietal, and temporal cortices.
The tau pathology, which included classical NFTs, NTs,
and plaque-associated neurites, was severe in the CA1 hip-
pocampal subregion, entorhinal cortex, and fusiform gyrus,
Fig. 1. (A) Sequencing chromatograms. c.454GA/p.A152T variant in p
showing segregation of the variant with the disease. For interpretation of th
of this article.and it corresponded to Braak and Braak stage IV (Fig. 2).The tau inclusions were both 3R- and 4R-tau positive.
Neither TDP-43-related pathology nor argyrophilic grain
disease was observed.
After re-visiting the neuropathology of this case, our
findings, as noted earlier, were not compatible with a path-
ological diagnosis of PEP. One might argue that the tau
pathology, including the abundant NFTs and NTs in the
substantia nigra, and the milder tau pathology in the sub-
thalamic nucleus and globus pallidus can be entirely “age-
related” (Mattila et al., 2002). In this scenario, the nigral cell
loss would be unrelated to the nigral tau pathology, and the
absence of -synuclein pathology and negative genetics in
the PARK2 and LRRK2 genes would indicate that an, as yet,
unidentified neurodegenerative process was responsible for the
underlying nigral cell loss. An alternative hypothesis is that the
mild subcortical tau pathology with deposition of both 3R- and
4R-tau is related to the MAPT p.A152T mutation and an
atypical tauopathy is responsible for the nigral cell loss.
3.1.3. Case 2
3.1.3.1. Clinical summary and neuropathology. When in
her late 50s, this English woman began to develop a sym-
metrical akinetic rigid syndrome. Two years later, exami-
nation revealed hypomimia, drooling, predominant axial
rigidity with mild symmetrical limb rigidity, brisk deep
tendon reflexes, and flexor plantar response. A diagnosis of
Parkinson’s disease was made; however, there was no re-
sponse to 700 mg/day of levodopa therapy. Her symptoms
(upper panel) and patient 2 (lower panel). (B) Family tree of patient 2
nces to color in this figure legend, the reader is referred to the Web versionatient 1
e referegradually deteriorated, and 7 years later, she developed
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experience daily episodic dystonic spasms with an opistho-
tonus posture and oculogyric crisis. Examination in between
these episodes revealed normal pursuit and saccadic eye
movements, fixed retrocollis, slow tongue movement, anar-
thria, severe axial and limb rigidity, and dystonic posturing
of the feet. Her cognitive function remained intact. The
presence of oculogyric crisis prompted the neurologist to
revise the diagnosis to PEP in the last year of her life. She
died after disease duration of 10 years. However, in view of
her lack of levodopa response, short disease duration, and
the lack of encephalitis history, the clinical diagnosis of PEP
would be very unlikely.
She has three younger sisters (Fig. 1). The second sister,
now in her mid 80s, has developed dementia with short-term
memory impairment, executive dysfunction, disorientation
to time, and required assistance with dressing and house-
work. She has normal mobility. Her youngest sister, in her
mid 70s, complains of forgetfulness but remains indepen-
dent. These sisters were assessed in person and over the
telephone, blind to the genetic analysis. Her third sister
remains well. Both cognitively impaired sisters carried the
mutation, whereas the healthy sister did not.
Review of this case with immunohistochemistry using
the AT8, 3R-tau, and 4R-tau antibodies indicated that the
overall neuropathological findings fulfilled the diagnostic
criteria for PSP (Ince et al., 2008; Litvan et al., 1996), as
there were moderate numbers of AT8 and 4R-positive and
3R-negative tufted astrocytes, NFTs, NTs, and coiled bod-
Fig. 2. Case 1: Figure (A) shows severe loss of neuromelanin-containing n
pigment (arrow head). Non-pigmented neurons are still present in this regi
in the nigra neurons. Figure (C) shows NFTs, NTs, and neuritic plaques
chemistry; bar on (A) represents 80 microns on A, 20 microns on B, and 40
the reader is referred to the Web version of this article.ies in the caudate, and similar, but milder, tau pathology wasseen in the putamen. In addition, there was also severe
gliosis and neuronal cell loss in the substantia nigra; signif-
icant reduction in size, nerve cell loss, and gliosis in the
globus pallidus and subthalamic nucleus; but relatively
good preservation of the cerebellar dentate nucleus and
superior cerebellar peduncle. These findings, together with
both neuronal and glial tau pathology in basal ganglia, brain-
stem, and cerebellar nuclei and relatively mild tau pathology in
the cerebral cortex, pontine base, and cerebellar dentate nu-
cleus, were in favor of the neuropathological diagnosis of the
pallido-nigro-luysial atrophy variant of PSP (PSP-PNLA)
(Ahmed et al., 2008). The age-related neurofibrillary pathology
corresponded to Braak and Braak stage II; there was no evi-
dence of argyrophilic grain disease (Fig. 3).
3.2. Secondary sequencing
After obtaining the findings outlined earlier in the article,
we screened exon 7 of the MAPT gene in 114 PSP, 8 CBD,
and 48 idiopathic Parkinson’s disease cases from the QSBB
archival collection. The mutation was identified in a case of
CBD. More surprisingly, it was also found in one of the
idiopathic Parkinson=s disease cases.
3.2.1. Case 3
3.2.1.1. Clinical summary and neuropathology. The CBD
case developed symptoms in the mid-sixth decade, with
early word finding difficulty and right-sided rigidity and
gait difficulty evolving through nonfluent aphasia to mut-
in the ventral tier of the substantia nigra (white asterisks), gliosis, and free
e substantia nigra (arrows). Figure (B) shows scattered tau-positive NFTs
CA1 hippocampal sub-region. (A—H&E, B and C—AT8 immunohisto-
ns on C). For interpretation of the references to color in this figure legend,eurons
on of th
in the
microism, increasing dependency, and death 11 years after
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of dementing illness. The pathology included achromatic
swollen neurons in the neocortex and limbic areas, nu-
merous pretangles and NFTs, dense meshwork of tau-
positive threads, astrocytic plaques in the frontal, tempo-
ral, and parietal cortices, and tau-positive threads and
some coiled bodies in subcortical white matter. Addition-
ally there were numerous TDP-43-positive neuronal cy-
toplasmic inclusions (NCIs) and neuronal intranuclear
inclusions in globus pallidus, caudate, and putamen and
severe cell loss in substantia nigra.
3.2.2. Case 4
3.2.2.1. Clinical summary and neuropathology. In his late
40s, this man developed an anxiety disorder and poor con-
centration, which resulted in him getting dismissed from his
job. In the following year, he started to stutter and was
diagnosed with depression. Two years later, he had memory
loss, executive impairment, and slowness in movement.
After the subsequent findings of markedly reduced tracer
reuptake in the basal ganglia on [123I]FP-CIT DAT images,
a diagnosis of Parkinson’s disease with dementia was made
Fig. 3. Case 2: Figure (A) shows a neuron with tau-positive NFT and fine N
tau-positive lesion containing 4-repeat tau isoform. (A and B—AT8 immun
icrons on A, 40 microns on figure B, and 15 microns on C). For interpre
eb version of this article.when he was in his early 50s. He was commenced on elevodopa therapy with moderate response. His cognitive
function deteriorated markedly in the following year with
fluctuating consciousness, disorientation, urinary inconti-
nence, severe dementia, visual hallucination, myoclonus,
and left-sided predominant akinetic rigidity. He died 7 years
after the onset of his first symptoms.
Neuropathological findings included moderate to se-
vere cell loss in the substantia nigra in association with
-synuclein-positive Lewy bodies and Lewy neurites.
requent cortical Lewy bodies were observed in the fron-
al, temporal, parietal, cingulate gyrus, and transentorhi-
al cortices, corresponding to Braak stage 6 (Braak et al.,
003), diffuse neocortical Lewy body-type pathology ac-
ording to consensus criteria (McKeith et al., 2005).
FTs were found in the hippocampus, entorhinal and
ransentorhinal cortices, which were consistent with
raak and Braak II. There were very few tau-positive
Ts in the caudate nucleus, midbrain tegmentum, and
eriaqueductal gray. There was a single NFT in the locus
oeruleus. A “low” level of Alzheimer disease pathologic
hange (A1, B1, C0) was identified (Hyman et al., 2012).
he neuropathological diagnoses were Parkinson’s dis-
he caudate. Figure (B) shows tufted astrocytes and NTs. Figure (C) shows
hemistry, C—4-repeat tau immunohistochemistry; bar on A represents 20
f the references to color in this figure legend, the reader is referred to theTs in t
ohistoc
tation oase with dementia and pathological aging.
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Our intention in this study was to try and understand
whether there were genetic factors in the MAPT gene that
contributed to those cases with complex tauopathies, previ-
ously often diagnosed as PEP. Our finding of the p.A152T
MAPT mutation in two of eight of these cases, together with
the previous report from Kovacs et al. (2011) with the
limited segregation in the family of proband (case 1), to-
gether with its absence from the control subjects we se-
quenced and its rarity in public databases, supports the view
that this variant contributes to disease risk. The finding that
the mutation occurs in one of eight cases of CBD could also
be adduced to support this view.
However, the identification of the variant in a case of
idiopathic PD was a surprise, even though this case is
unusual for such a young case in having a considerable
burden of tau pathology. Additionally, the disease picture in
all the cases we report varies both clinically and patholog-
ically, and although we show some evidence for segregation
in the single family in which this analysis was possible, in
most cases family history was not reported and, unlike in
classic cases with MAPT mutations, the tau pathology was
very varied, both in morphology and distribution: being 4
repeat in cases 2 and 3 and a classic mixture of 3 and 4
repeat in cases 1 and 4.
The position of the variant is interesting in that it creates
an additional phosphorylation site in the tau protein, and tau
hyperphosphorylation has been repeatedly suggested to con-
tribute to tangle formation and cell death sites (Rademakers
et al., 2004). One plausible suggestion is that this mutation
contributes to disease pathogenesis through the creation of
an additional phosphorylation site, but this is not sufficient,
of itself, to cause disease in the way that the MAPT splice
and P301L mutations do. The mutated residue is next to
Thr153 (T153), a phosphorylation site which is a target for
proline-directed kinases such as mitogen-activated protein
kinase (MAPK), cell division protein kinase 5 (cdk5), and
glycogen synthase kinase-3 alpha (GSK3). Using an anti-
ody against the phosphorylated T153 (pT153), Augusti-
ack et al. (2002) showed that although intraneuronal and
xtraneuronal tangles were labeled, the dominant staining
as punctate and of pretangles within morphologically in-
act neurons, with normal cellular integrity and well-pre-
erved dendrites. A similar staining pattern of pretangles
as observed with the conformation-specific TG3 antibody
Jicha et al., 1997) and a phospho-tau-specific pS262 anti-
ody, and they suggest that these antibodies label an early
tage of tangle formation characterized by punctate inclu-
ions that precede fully fledged fibrillar tangles (Augusti-
ack et al., 2002). It is possible that the additional Thr152
ncreases phosphorylation and thus further contributes to the
arly stages of the fibrillogenic pathway.
LRRK2 mutations offer a precedent for this complex
elationship between mutations and disease. Some muta- sions (e.g., p.G2019S) cause disease in an almost fully
enetrant autosomal dominant fashion (Paisán-Ruíz et al.,
004), whereas others (e.g., p.G2385R) increase disease risk
y a modest amount (Tan et al., 2010). Additionally, and
lso similarly to the situation with regard to the p.A152T
APT variant, LRRK2 mutations cause variable pathology,
sually Lewy body pathology, but sometimes tangle or
DP-43 pathology (Zimprich et al., 2004). For the true role
f this variant in neurological disease to be determined,
learly very large numbers (thousands) of cases with vari-
us tauopathies and control subjects will need to be se-
uenced, and certainly until that time, these data would not
upport this mutation becoming part of the clinical test in
he way that the penetrant mutations are.
These data have also caused us to re-examine our views
n PEP. PEP has now become a historical illness with an
xception of a few sporadic cases. In the past, there was a
igh prevalence rate of PEP after the simultaneous outbreak
f encephalitis lethargica (von Economo’s encephalitis or
sleepy sickness” that was portrayed in the movie “Awak-
nings”) and H1N1 influenza A virus pandemics in Europe
rom the late 1910s until the mid-1920s (Economo, 1931). It
as been speculated, but never proven, that the influenza A
irus caused the encephalitis, which in turn led to a parkin-
onian disorder in a substantial number of sufferers (Calne
nd Lees, 1988). However, neither of our primary patients
ad a clear history of encephalitis or a flu-like illness pre-
eding the development of parkinsonian features, which
akes the clear diagnosis of PEP doubtful, especially in
iew of the genetic findings we report. PEP, like amyo-
rophic lateral sclerosis/parkinsonism-dementia comples of
uam (ALS/PDC) complex of Guam (Geddes et al., 1993),
as been a prevalent tauopathy, which appeared and then
isappeared without any clear explanation being found
Steele, 2005). In both these cases and in the smaller tauopa-
hy outbreaks on the Kii peninsular and on St Martinique
Caparros-Lefebvre et al., 2006), our understanding of these
iseases has been limited by the collection and survival of
oo few samples for modern analytical investigations.
. Conclusions
We conclude that the rare p.A152T variant is likely to
ncrease the susceptibility to the development of neurode-
enerative conditions with abnormal tau accumulation. Fur-
her functional studies are necessary to fully dissect the
unctional consequences and precise pathogenic mecha-
isms associated with this mutation. The evidence for the
athogenicity of this variant is not strong enough for these
ata to be used in genetic counseling.
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